BofA analyst Jason Gerberry raised the firm’s price target on United Therapeutics (UTHR) to $626 from $569 and keeps a Neutral rating on the shares. Based on the combined results of TETON-1 and -2, the firm believes there is a role for Tyvaso as both a monotherapy in those unable to tolerate anti-fibrotics and as an adjunct on top of anti-fibrotics, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics price target raised to $575 from $486 at Wells Fargo
- Balanced View on Tyvaso’s IPF Upside: Strong Phase 3 Momentum Offset by Valuation and Execution Risks
- Morning News Wrap-Up 3/30/26: Today’s Biggest Stock Market Stories!
- United Therapeutics rises 12.6%
- RBC sees high probability of approval in IPF after United’s TETON-1 clears bar